Kisspeptin Is Upregulated at the Maternal-Fetal Interface of the Preeclamptic-like BPH/5 Mouse and Normalized after Synchronization of Sex Steroid Hormones.

Gomes VCL, Woods AK, Crissman KR, Landry CA, Beckers KF, Gilbert BM, Ferro LR, Liu CC, Oberhaus EL, Sones JL

Reproductive medicine (Basel, Switzerland)14 Oct 2022Cited by 5 (Europe PMC)

PMID37538930PMCIDPMC10399610DOI10.3390/reprodmed3040021PepBankPUB-37538930

Summary

Insufficient invasion of conceptus-derived trophoblast cells in the maternal decidua is a key event in the development of early-onset preeclampsia (PE), a subtype of PE associated with high maternal and fetal morbidity and mortality. Kisspeptins, a family of peptides previously shown to inhibit trophoblast cell invasion, have been implicated in the pathogenesis of early-onset PE. However, a role of kisspeptin signaling during the genesis of this syndrome has not been elucidated. Herein, we used the preeclamptic-like BPH/5 mouse model to investigate kisspeptin expression and potential upstream regulatory mechanisms in a PE-like syndrome. Expression of the kisspeptin encoding gene, Kiss1, and the 10-amino-acid kisspeptide (Kp-10), are upregulated in the non-pregnant uterus of BPH/5 females during diestrus and in the maternal-fetal interface during embryonic implantation and decidualization. Correspondingly, the dysregulation of molecular pathways downstream to kisspeptins also occurs in this mouse model. BPH/5 females have abnormal sex steroid hormone profiles during early gestation. In this study, the normalization of circulating concentrations of 17β-estradiol (E2) and progesterone (P4) in pregnant BPH/5 females not only mitigated Kiss1 upregulation, but also rescued the expression of multiple molecules downstream to kisspeptin and ameliorated adverse fetoplacental outcomes. Those findings suggest that uterine Kiss1 upregulation occurs pre-pregnancy and persists during early gestation in a PE-like mouse model. Moreover, this study highlights the role of sex steroid hormones in uteroplacental Kiss1 dysregulation and the improvement of placentation by normalization of E2, P4 and Kiss1.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Other
In the preeclamptic-like BPH/5 mouse, expression of the kisspeptin gene Kiss1 was upregulated in the non-pregnant uterus and at the maternal-fetal interface.
In plain wordsIn preeclamptic-like mice, the gene for the body's own kisspeptin was more active in the uterus and at the maternal-fetal interface.
Peptide
Kisspeptin-10
Outcome
IncreaseKiss1 gene expression in the maternal-fetal interface and uterus
Study
mousen: not reported in source
BPH/5 preeclamptic-like mouse
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Expression of the kisspeptin encoding gene, Kiss1, and the 10-amino-acid kisspeptide (Kp-10), are upregulated in the non-pregnant uterus of BPH/5 females during diestrus and in the maternal-fetal interface during embryonic implantation and decidualization
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we used the preeclamptic-like BPH/5 mouse model to investigate kisspeptin expression and potential upstream regulatory mechanisms in a PE-like syndrome.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3753893001
02AnimalEndogenous levelAnimal study (in vivo)Other
In the preeclamptic-like BPH/5 mouse, expression of the 10-amino-acid kisspeptide Kp-10 was upregulated in the non-pregnant uterus and at the maternal-fetal interface.
In plain wordsIn preeclamptic-like mice, the body's own Kp-10 was higher in the uterus and at the maternal-fetal interface.
Peptide
Kisspeptin-10
Outcome
IncreaseKisspeptide (Kp-10) expression in the maternal-fetal interface and uterus
Study
mousen: not reported in source
BPH/5 preeclamptic-like mouse
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Expression of the kisspeptin encoding gene, Kiss1, and the 10-amino-acid kisspeptide (Kp-10), are upregulated in the non-pregnant uterus of BPH/5 females during diestrus and in the maternal-fetal interface during embryonic implantation and decidualization
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we used the preeclamptic-like BPH/5 mouse model to investigate kisspeptin expression and potential upstream regulatory mechanisms in a PE-like syndrome.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3753893002
03AnimalEndogenous levelAnimal study (in vivo)Other
In pregnant BPH/5 mice, normalizing circulating 17β-estradiol and progesterone mitigated Kiss1 upregulation.
In plain wordsIn preeclamptic-like mice, restoring normal estradiol and progesterone levels reduced the raised activity of the body's own kisspeptin gene.
Peptide
Kisspeptin-10
Outcome
DecreaseKiss1 upregulation after normalization of E2 and P4
Study
mousen: not reported in source
BPH/5 preeclamptic-like mouse
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
the normalization of circulating concentrations of 17β-estradiol (E2) and progesterone (P4) in pregnant BPH/5 females not only mitigated Kiss1 upregulation
1 context sentence(design, population, supporting numbers)
Summary · context
Herein, we used the preeclamptic-like BPH/5 mouse model to investigate kisspeptin expression and potential upstream regulatory mechanisms in a PE-like syndrome.
This result measures the body's own Kisspeptin-10. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3753893003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 09:43 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.